Therapeuticsmd Inc   (TXMD)
Other Ticker:  
Price: $2.6350 $0.10 3.740%
Day's High: $2.66 Week Perf: 12.13 %
Day's Low: $ 2.55 30 Day Perf: 16.59 %
Volume (M): 51 52 Wk High: $ 4.99
Volume (M$): $ 133 52 Wk Avg: $3.22
Open: $2.59 52 Wk Low: $1.95

 Market Capitalization (Millions $) 28
 Shares Outstanding (Millions) 11
 Employees 325
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) 68
 Cash Flow (TTM) (Millions $) -28
 Capital Exp. (TTM) (Millions $) 0

Therapeuticsmd Inc
TherapeuticsMD Inc is a pharmaceutical company based in Boca Raton, Florida. The company focuses on developing and commercializing innovative products for women's health. Their mission is to improve the lives of women at all stages through life with high-quality, innovative and effective products.

TherapeuticsMD is known for their prescription hormone therapy products such as BIJUVA, which is a combination of estradiol and progesterone designed to treat moderate to severe vasomotor symptoms of menopause. It is the first and only FDA-approved hormone therapy that combines bio-identical estradiol and progesterone in a single, oral capsule dose.

Another hormone therapy product from TherapeuticsMD is IMVEXXY, which is an ultra-low dose vaginal estradiol product designed to help women with moderate to severe painful sex due to menopause. The company also offers a line of vitamins and supplements to support women's health.

In addition to their hormone therapy products, TherapeuticsMD also has a research and development team that is dedicated to discovering and developing new products aimed at treating different women's health conditions. Their team of experts is constantly working on ways to improve women's health through innovative and effective products.

TherapeuticsMD Inc has also made notable progress in their commitment to sustainability, as shown through their recently released Sustainability Report. The report highlights their initiatives in resource reduction, environmental stewardship, and social responsibility.

Overall, TherapeuticsMD Inc is a company that is dedicated to improving women's health through innovative and effective products. With a strong focus on research and development, the company is poised to continue growing and expanding their product offerings in the women's health space.

   Company Address: 951 Yamato Road Boca Raton 33431 FL
   Company Phone Number: 961-1900   Stock Exchange / Ticker: NASDAQ TXMD
   TXMD is expected to report next financial results on April 06, 2024.


Stock Performances by Major Competitors

5 Days Decrease / Increase
AGRX        8.17% 
TEVA        1.05% 
• View Complete Report

Therapeuticsmd Inc

TherapeuticsMD Inc Shines Brightly During the Entirety of Q3 2023!

TherapeuticsMD Inc (NASDAQ: TXMD) recently reported its financial results for the third quarter of 2023, showing losses of $0.32 per share. This is a significant improvement from the same quarter last year when the losses were $3.13 per share. In the prior reporting season, the company incurred losses of $0.24 per share.
Furthermore, the net shortfall in the third quarter of 2023 amounted to $3.378 million, a considerable decrease from the deficit of $28.965 million reported in the same quarter the previous year. These positive financial results indicate that TherapeuticsMD Inc is making progress in its transition into a royalty-based business.
Marlan D. Walker, the Chief Executive Officer of TherapeuticsMD, emphasized the company's commitment to cost control in order to maximize the value of its royalty assets. This strategy seems to be yielding positive outcomes, as evidenced by the improved financial performance.
The market also responded positively to TherapeuticsMD Inc's recent performance, as its shares gained 18% over the past week. Compared to the previous year, the shares have gone up by an impressive 56.78%. Additionally, the shares currently trade 21% above their 52-week low.

Therapeuticsmd Inc

TherapeuticsMD Inc Experiences Dismal Second Quarter Financial Results with a Staggering -98.47% Drop in Revenue

TherapeuticsMD Inc, a renowned pharmaceutical company, has recently released its Jun 30, 2023 financial results, reflecting a downward spiral in revenue and substantial increase in net loss per share. This article will delve into the implications of these disappointing figures and speculate on the potential impacts they may have on TherapeuticsMD's future prospects.
Revenue Plunge and Net Loss Swell:
According to the financial results, TherapeuticsMD experienced a significant decline in revenue during the reporting period, plummeting by a formidable -98.47% to a mere $0.44 million. This sharp drop indicates a considerable decrease in sales or operational challenges faced by the company. Moreover, the net loss per share soared from $-0.37 in the previous year to $-0.24, signaling a worsening financial situation.

Therapeuticsmd Inc

Therapeuticsmd Inc Sees Growth in Income per Employee, but Challenges Remain for Major Pharmaceutical Preparations Industry

As a journalist, I have analyzed the first quarter 2023 financial results of Therapeuticsmd Inc. The report indicates that there has been a growth in income per employee on a trailing twelve month basis. This is a positive development for Therapeuticsmd Inc as the contribution of the employees towards the company's profits has reached a new high of $ per employee. However, it is important to note that the overall ranking of the company has deteriorated compared to the fourth quarter of 2022.
The Major Pharmaceutical Preparations industry has seen employees of 16 other companies reaching higher income per employee. This indicates that although Therapeuticsmd Inc is performing well in terms of employee contribution, there is still scope for improvement to catch up with the other players in the industry.
The report also highlights that the company has incurred losses in the most recent fiscal period. Therapeuticsmd Inc lost money of $-0.37 per share compared to $-5.69 a year ago. The Income per Share also fell from $8.19 per share from the prior reporting period. The decline in the Income per Share is concerning for the company as it indicates a decline in profitability.


Therapeuticsmd Inc's Segments
• View Complete Report


About us


CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com